Lymphadenectomy via the transperitoneal (anterior abdominal) approach for cancer of the testis

This article discusses 103 patients with a nonseminomatous testicular germ cell tumor. Treatment of 87 patients in clinical Stages I, II‐A, and II‐B consisted of bilateral retroperitoneal lymph node dissection. In Stage I (54 patients), no further treatment was given. The three‐year survival was 96%, while recurrence‐free survival was 98%. Of 33 patients in Stages II‐A and II‐B, 26 received adjuvant chemotherapy with dactinomycin, and ten of these were given radiotherapy (peritoneum/mediastinum) as well. The three‐year survival was 88% and recurrence‐free survival was 85%. Seven patients in Stages II‐A and II‐B received no adjuvant chemotherapy; four of them died. Treatment of 14 patients in Stage II‐C primarily consisted of dactinomycin therapy, subsequently combined with surgery and radiotherapy. The three‐year survival was 28.5%. These findings raise the question whether adjuvant single‐agent chemotherapy with dactinomycin for patients with a nonseminomatous testicular germ cell tumor should not be re‐evaluated.

show abstract

Die malignen germinalen Hodentumoren

Sigel¹,

Held²

1965

Ergebnisse Der Chirurgie Und Orthopädie

View full text Add to dashboard Cite

Lymphadenectomy via the transperitoneal (anterior abdominal) approach for cancer of the testis

Cited by 10 publications

References 3 publications

Comment: The Lymph Node Barrier

Comment: The Lymph Node Barrier

Results of retroperitoneal lymph node dissection and postoperative adjuvant chemotherapy with dactinomycin in the treatment of retroperitoneal metastases of nonseminomatous testicular germ cell tumors

Die malignen germinalen Hodentumoren

Contact Info

Product

Resources

About